Agenus shared on LinkedIn:
“We will present new research on BOT+BAL in metastatic colorectal cancer at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting next month.
Our presentations will include clinical features of long-term survivor data in patients with refractory microsatellite-stable metastatic colorectal cancer treated with BOT+BAL, as well as translational research evaluating BOT+BAL in combination with MiNK Therapeutics’ agenT-797 in a preclinical model of colorectal cancer liver metastases.
See our presentation details below and in our press release.
We will present new research on BOT+BAL in metastatic colorectal cancer at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting next month.
Our presentations will include clinical features of long-term survivor data in patients with refractory microsatellite-stable metastatic colorectal cancer treated with BOT+BAL, as well as translational research evaluating BOT+BAL in combination with MiNK Therapeutics’ agenT-797 in a preclinical model of colorectal cancer liver metastases.
See our presentation details below and in our press release.”
Other articles about SITC on OncoDaily.